GSK.L vs. AVGO
GSK.L (GlaxoSmithKline plc) and AVGO (Broadcom Inc.) are both stocks. GSK.L operates in Drug Manufacturers - General (Healthcare), while AVGO operates in Semiconductors (Technology). Over the past 10 years, GSK.L returned 6.03%/yr vs 41.68%/yr for AVGO. At a 0.12 correlation, their price movements are largely independent.
Performance
GSK.L vs. AVGO - Performance Comparison
Loading charts...
Different Trading Currencies
GSK.L is traded in GBp, while AVGO is traded in USD. To make them comparable, the AVGO values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, GSK.L achieves a 10.61% return, which is significantly lower than AVGO's 11.19% return. Over the past 10 years, GSK.L has underperformed AVGO with an annualized return of 6.03%, while AVGO has yielded a comparatively higher 41.68% annualized return.
GSK.L
- 1D
- 1.10%
- 1M
- 6.15%
- YTD
- 10.61%
- 6M
- 10.61%
- 1Y
- 32.87%
- 3Y*
- 17.81%
- 5Y*
- 6.60%
- 10Y*
- 6.03%
AVGO
- 1D
- -0.82%
- 1M
- -7.52%
- YTD
- 11.19%
- 6M
- 6.31%
- 1Y
- 52.80%
- 3Y*
- 63.80%
- 5Y*
- 56.69%
- 10Y*
- 41.68%
GSK.L vs. AVGO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 10.61% | 41.46% | -3.51% | 4.94% | -25.94% | 26.66% | -20.76% | 25.32% | 19.02% | -10.82% |
AVGO Broadcom Inc. | 11.19% | 39.90% | 114.17% | 93.98% | -2.96% | 57.97% | 40.62% | 24.14% | 8.24% | 35.37% |
Correlation
The correlation between GSK.L and AVGO is -0.15, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.08 |
Correlation (5Y) Calculated over the trailing 5-year period | -0.05 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Aug 6, 2009 | 0.12 |
The correlation between GSK.L and AVGO shifts across timeframes, from -0.15 (1 year) to 0.12 (all time), reflecting how their relationship changes across market environments.
Fundamentals
GSK.L:
£80.83B
AVGO:
$1.86T
GSK.L:
£1.42
AVGO:
$6.01
GSK.L:
13.93
AVGO:
63.58
GSK.L:
0.31
AVGO:
0.79
GSK.L:
2.48
AVGO:
24.70
GSK.L:
4.53
AVGO:
21.24
GSK.L:
£32.78B
AVGO:
$75.47B
GSK.L:
£23.84B
AVGO:
$50.53B
GSK.L:
£11.56B
AVGO:
$41.76B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK.L vs. AVGO — Risk / Return Rank
GSK.L
AVGO
GSK.L vs. AVGO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and Broadcom Inc. (AVGO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK.L | AVGO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.12 | ||
| Sortino ratioReturn per unit of downside risk | +0.30 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.23 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.78 | 1.92 | -0.14 |
| Martin ratioReturn relative to average drawdown | 4.57 | 4.25 | +0.32 |
Loading charts...
Drawdowns
GSK.L vs. AVGO - Drawdown Comparison
The maximum GSK.L drawdown since its inception was -42.39%, roughly equal to the maximum AVGO drawdown of -42.16%. Use the drawdown chart below to compare losses from any high point for GSK.L and AVGO.
Loading charts...
Drawdown Indicators
| GSK.L | AVGO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.39% | -42.16% | -0.23% |
Max Drawdown (1Y)Largest decline over 1 year | -18.35% | -27.60% | +9.25% |
Max Drawdown (3Y)Largest decline over 3 years | -27.42% | -42.09% | +14.67% |
Max Drawdown (5Y)Largest decline over 5 years | -42.39% | -42.09% | -0.30% |
Max Drawdown (10Y)Largest decline over 10 years | -42.39% | -42.16% | -0.23% |
Current DrawdownCurrent decline from peak | -11.02% | -20.30% | +9.28% |
Average DrawdownAverage peak-to-trough decline | -12.78% | -7.46% | -5.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.93% | 12.46% | -5.53% |
Volatility
GSK.L vs. AVGO - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK.L) is 6.10%, while Broadcom Inc. (AVGO) has a volatility of 20.40%. This indicates that GSK.L experiences smaller price fluctuations and is considered to be less risky than AVGO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK.L | AVGO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.10% | 20.40% | -14.30% |
Volatility (6M)Calculated over the trailing 6-month period | 18.09% | 33.99% | -15.90% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.04% | 44.73% | -19.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.68% | 42.53% | -18.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.09% | 39.06% | -16.97% |
Dividends
GSK.L vs. AVGO - Dividend Comparison
GSK.L's dividend yield for the trailing twelve months is around 3.38%, more than AVGO's 0.65% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AVGO Broadcom Inc. | 0.65% | 0.70% | 0.94% | 1.71% | 3.02% | 2.24% | 3.05% | 3.54% | 3.11% | 1.87% | 1.43% | 1.13% |
GSK.L GlaxoSmithKline plc | 3.38% | 3.51% | 4.53% | 3.84% | 5.30% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% |
Financials
GSK.L vs. AVGO - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Broadcom Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK.L vs. AVGO - Profitability Comparison
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
AVGO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Broadcom Inc. reported a gross profit of 14.92B and revenue of 22.19B. Therefore, the gross margin over that period was 67.2%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
AVGO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Broadcom Inc. reported an operating income of 10.87B and revenue of 22.19B, resulting in an operating margin of 49.0%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
AVGO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Broadcom Inc. reported a net income of 9.31B and revenue of 22.19B, resulting in a net margin of 42.0%.
Frequently Asked Questions
GSK.L and AVGO have a correlation of -0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GSK.L and AVGO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer